ArticleBritish journal of cancer2009

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.

D Yoshikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.